- Galecto Inc GLTO has announced the treatment of the first patient in a Phase 2a trial of its oral LOXL2 inhibitor GB2064 in myelofibrosis.
- Myelofibrosis, a form of chronic leukemia, is a rare type of blood cancer in which the normal bone marrow is destroyed by fibrous scar tissue that does not produce blood cells.
- The open-label MYLOX-1 trial is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of orally administered GB2064 in 16 patients over 9 months.
- The trial will also assess the impact on fibrosis and quantification of the tissue targeting of GB2064 and other aspects of clinical response in myelofibrosis.
- Price Action: GLTO shares are up 5.4% at $4.08 during the premarket session on the last check Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
